(Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
| Data: |
2022 |
| Resum: |
The comorbidity burden is an important risk factor for overall survival (OS) in several hematological malignancies. This observational prospective study was conducted to evaluate the impact of individual comorbidities on survival in a multicenter series of 668 patients with primary myelofibrosis (PMF) or MF secondary to polycythemia vera (PPV-MF) or essential thrombocythemia (PET-MF). Hypertension (hazard ratio (HR) = 4. 96, p < 0. 001), smoking (HR = 5. 08, p < 0. 001), dyslipidemia (HR = 4. 65, p < 0. 001) and hepatitis C virus (HCV) (HR = 4. 26, p = 0. 015) were most adversely associated with OS. Diabetes (HR = 3. 01, p < 0. 001), pulmonary disease (HR = 3. 13, p < 0. 001) and renal dysfunction (HR = 1. 82, p = 0. 037) were also associated with an increased risk of death. Multivariate analysis showed that pulmonary disease (HR = 2. 69, p = 0. 001), smoking (HR = 3. 34, p < 0. 001), renal dysfunction (HR = 2. 08, p = 0. 043) and HCV (HR = 11. 49, p = 0. 001) had a negative impact on OS. When ruxolitinib exposure was included in the model, the effect of each comorbidity on survival was modified. Therefore, individual comorbidities should be taken into account in determining the survival prognosis for patients with MF. |
| Nota: |
Conflicts of Interest: M.G.-F. provided consultancy services to Pfizer, Novartis, Jazz Pharmaceuticals and Astellas. R.G.-D. provided consultancy services to Abbie, Novartis, Bristol-Myers Squibb, and Janssen, and received research funding from Bristol-Myers Squibb. F.F.-M. received a grant from Incyte Corporation (FFIS-CNT-2020-8) and from CTI Biophama Corp (CFE/BI/72-19; FFIS-CNT-2019-4). The remaining authors declare no competing financial interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. |
| Nota: |
Funding: This research was supported by an unrestricted grant from Novartis Pharmaceutical. The opinions expressed in this article are those of the authors and do not necessarily reflect those of Novartis. |
| Nota: |
Acknowledgments: The authors thank all of the patients and their families who contributed to this study and the participating site study data coordinators. This article was produced through the collaborative efforts of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN). The study was sponsored by Novartis Pharmaceuticals, Inc. |
| Drets: |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.  |
| Llengua: |
Anglès |
| Document: |
Article ; recerca ; Versió publicada |
| Matèria: |
Myelofibrosis ;
Comorbidities ;
Survival ;
Prognosis |
| Publicat a: |
Cancers, Vol. 14 Núm. 9 (5-1 2022) , p. 2331, ISSN 2072-6694 |
visitant ::
identificació
(Universidad de Málaga)
